Retatrutide

Mechanism · Dosing · Effects (10 mg protocol — fast titration to 4 mg)

Overview

Retatrutide (LY-3437943) is an investigational triple-agonist acting on GLP-1, GIP, and glucagon receptors to reduce appetite, enhance insulin sensitivity, slow gastric emptying, and increase energy expenditure. It is administered once weekly via subcutaneous injection. This guide provides a 10 mg vial–based dosing, reconstitution, .

Mechanism (how it works)

Triple receptor activation:
GLP-1 + GIP + glucagon → enhanced satiety, better glucose regulation, increased fat oxidation.
Appetite & metabolism synergy:
Appetite suppression begins at low doses; metabolic benefits develop progressively with consistent weekly dosing.

Dosing & Reconstitution Guide (practical)

Route: Subcutaneous injection, once weekly
Storage: Keep reconstituted solution refrigerated (2–8 °C), protected from light
Goal: Reach 4 mg/week using a faster, clinically aligned escalation

Reconstitution

10 mg vial + 1.0 mL bacteriostatic water → 10 mg/mL

1 mg = 0.1 mL = 10 units (U-100 insulin syringe)
0.5 mg = 0.05 mL = 5 units

Fast-Titration Protocol (ends at 4 mg)

Weeks 1–2:

1 mg weekly
→ 0.1 mL (10 units)

Weeks 3–4:

2 mg weekly
→ 0.2 mL (20 units)

Weeks 5–6:

3 mg weekly
→ 0.3 mL (30 units)

Weeks 7–16:

4 mg weekly (maintenance dose)
→ 0.4 mL (40 units)

This provides a controlled but faster escalation, reaching the target therapeutic dose by Week 7.

Effects & Benefits

Weight reduction:
Dose-dependent, with stronger results once reaching 3–4 mg.
Metabolic improvements:
Better blood sugar control, improved insulin sensitivity, lower fasting glucose.
Reduced appetite:
Strong satiety, slower gastric emptying, lower food intake.

Side Effects & Safety Notes

Common:
Nausea, vomiting, diarrhea, constipation, abdominal discomfort — typically during dose increases.
Titration-dependent:
Faster escalation may increase GI symptoms; reduce dose or repeat previous week if poorly tolerated.
Safety notice:
Retatrutide is investigational. Do not use outside medical supervision. Stop and seek medical care for severe or unusual reactions.

Go Back